ReviewThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy.
Review in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 63 citations in OpenAlex.
- Trial
- Optimising Paediatric Medication Adherence Through Innovative Drug Formulations and Delivery Systems.Clinical pharmacokinetics · 2026Review
- DoE- and PBBM-Driven Formulation Development of an Extended-Release Donepezil Tablet.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Evaluation of Efficacy and Review of Side Effect Profile in Epilepsy Patients Treated with Extended-Release Levetiracetam.Pakistan journal of medical sciences · 2025Article
- Review
- Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator.Scientific reports · 2025Article
- Antiseizure Medications: Advancements, Challenges, and Prospects in Drug Development.Current neuropharmacology · 2025Review
- Development and Evaluation of a Cost-Effective, Carbon-Based, Extended-Release Febuxostat Tablet.Molecules (Basel, Switzerland) · 2024Article
- Timing Matters: Time of Day Impacts the Ergogenic Effects of Caffeine-A Narrative Review.Nutrients · 2024Review
- Self-Assembled PLGA-Pluronic F127 Microsphere for Sustained Drug Release for Osteoarthritis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population.Clinical and translational science · 2024Review
- Dosage optimization for reducing tumor burden using a phenotype-structured population model with a drug-resistance continuum.Mathematical medicine and biology : a journal of the IMA · 2024Article
- Review
- Sensors and Devices Guided by Artificial Intelligence for Personalized Pain Medicine.Cyborg and bionic systems (Washington, D.C.) · 2024Review
- Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems.Nature reviews. Drug discovery · 2023Review
- Article
- Review
- Sudden Unexpected Death in Epilepsy (SUDEP): How Do We Prevent This Childhood Tragedy?The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Packaging and Delivery of Asthma Therapeutics.Pharmaceutics · 2021Review
- What should patients do if they miss a dose of medication? A theoretical approach.Journal of pharmacokinetics and pharmacodynamics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is one of the most common chronic neurologic disorders that affects individuals of all ages. It is primarily managed with antiepileptic drugs (AEDs), with the goal of maintaining complete seizure control combined with minimal or no adverse effects. Oral administration is the mainstay of AED delivery for patients with chronic epilepsy and consists essentially of immediate-release (IR) and modified-release (delayed-release and extended-release [ER]) dosage formulations. Extended-release formulations (hydrophilic or hydrophobic matrix systems, reservoir systems, and osmotic-release systems) release a drug in a controlled manner during an extended period of time following administration. Extended-release formulations have many advantages compared with IR formulations, including simplification of dosing regimens, reduction in pill burden, and reduction in the peak-to-trough fluctuations in serum drug concentration that may be associated with a decreased risk of adverse effects and of seizures. These advantages have the potential to increase adherence to antiepileptic therapy, improve the quality of life of patients, and reduce health care costs. This article, which is intended as a practical guide for clinicians, reviews the properties of the different ER AED formulations currently available and discusses the advantages of ER over IR formulations. Subsequently, an explanation of the technologic basis of the different oral ER formulations, the critical attributes that differentiate ER products, and their individual strengths and weaknesses is provided. Specific recommendations to practitioners on treating patients with ER formulations are included.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.